Cellular Therapy
Latest News
Cancer groups offer guidance on immune-related adverse events
Both ASCO and NCCN have released guidelines with tips for managing the side effects of cancer immunotherapy agents.
Conference Coverage
High efficacy, no safety signals for herpes zoster vaccine post-HSCT
SALT LAKE CITY – The vaccine could offer safe, effective protection against herpes zoster in myeloma patients who are immunosuppressed.
Latest News
HCT-CI score may predict mortality for nonmalignant disease
SALT LAKE CITY – The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) is useful in hematologic malignancies, but it may also be...
From the Journals
Tisagenlecleucel looks effective in phase 2 study of young ALL patients
Tisagenlecleucel had transitory but high-grade toxicity in this population of children and young adults.
From the Journals
Checkpoint inhibitors look safe in rheumatology patients
The Mayo Clinic analysis examines 16 patients with rheumatologic diseases and cancer who received checkpoint inhibitor therapy.
From the Journals
A mismatched haplotype may improve outcomes in second BMT
Mortality risk was highest in patients who had progressive or refractory disease before a second transplant, or who relapsed within 6 months of a...
From the Journals
Autologous stem-cell transplantation for scleroderma beats cyclophosphamide in long term
Hematopoietic toxicity should be weighed against the benefits of transplantation.
Conference Coverage
How to manage cytokine release syndrome
ATLANTA – Don’t wait to give anticytokine therapy.
Conference Coverage
Updated ZUMA-1 data show durable CAR-T responses in B-cell lymphomas
ATLANTA – Updated results in 108 patients with refractory B cell lymphomas showed an ORR of 82%, including 58% complete responses, after a median...
Conference Coverage
Gene therapy regimen for XSCID shows rapid results in newly diagnosed infants
ATLANTA – The regimen combines a modified lentiviral vector with reduced exposure busulfan conditioning.
From the Journals
Cyclophosphamide after transplant reduced GVHD in myeloma patients
Anticancer agents may be more active after transplantation than before, researchers suggested.